pentobarbital will reduce the extent or impact of nateglinide by impacting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Observe.
pentobarbital will lessen the level or effect of trazodone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
pentobarbital will reduce the level or outcome of quetiapine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pentobarbital will decrease the extent or effect of suvorexant by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe. Strong CYP3A4 inducers could lower suvorexant efficacy; if greater suvorexant dose expected, never exceed twenty mg/day
Pentobarbital is not made use of commonly in medical medicine thanks to its inadequate safety profile, habituation, and deficiency of an antidote. All prescribing clinicians ought to be familiar with the drug's toxicity and adverse party profile. Neurologists can use pentobarbital for refractory status epilepticus.
pentobarbital will decrease the extent or impact of ziprasidone here by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Unidentified.
pentobarbital will lessen the level or impact of cevimeline by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Unfamiliar.
pentobarbital will lower the extent or influence of fentanyl by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Check Carefully. Coadministration of fentanyl with CYP3A4 inducers may lead to a minimize in fentanyl plasma concentrations, insufficient efficacy or, quite possibly, enhancement of a withdrawal syndrome in a very individual who has made Actual physical dependence to fentanyl.
pentobarbital will lessen the level or impact of triamcinolone acetonide injectable suspension by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
pentobarbital will lower the level or result of clozapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
pentobarbital will lower the extent or outcome of imatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unidentified.
pentobarbital will reduce the extent or effect of norgestrel by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Moderate CYP3A4 inducers may possibly reduce progestin concentration; think about usage of further barrier solutions
pentobarbital will lessen the level or result of nitrendipine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Not known.
Monoamine oxidase inhibitors (MAOI) might inhibit barbiturate metabolism and extend barbiturate outcomes; watch intently